Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | LTA4H | P09960 | 2/20 | 0.33 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CES2 | O00748 | 2/20 | 0.32 |
| ▸ | CES1 | P23141 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3394776 | 1.00 | TDP1 (0.34) | TDP1TSHRLTA4HPCSK9PTGS2 | |
| SCHEMBL49617 | 0.92 | TDP1 (0.38) | TDP1TSHRLTA4HPCSK9PTGS2 | |
| SCHEMBL6281632 | 0.90 | TDP1 (0.35) | TDP1TSHRLTA4HPCSK9PTGS2 | |
| SCHEMBL28811735 | 0.90 | TDP1 (0.35) | TDP1TSHRLTA4HPCSK9PTGS2 | |
| SCHEMBL9414101 | 0.90 | TDP1 (0.37) | TDP1TSHRLTA4HPCSK9PTGS2 | |
| SCHEMBL10585317 | 0.90 | TDP1 (0.37) | TDP1TSHRLTA4HPCSK9PTGS2 | |
| Hydrochloric Acid SCHEMBL28497176 | 0.90 | TDP1 (0.37) | TDP1TSHRLTA4HPCSK9PTGS2 | |
| Hydrochloric Acid SCHEMBL28975804 | 0.90 | TDP1 (0.37) | TDP1TSHRLTA4HPCSK9PTGS2 | |
| Bromide SCHEMBL1577209 | 0.90 | TDP1 (0.37) | TDP1TSHRLTA4HPCSK9PTGS2 | |
| SCHEMBL30514704 | 0.90 | TDP1 (0.37) | TDP1TSHRLTA4HPCSK9PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1544187-B1 | 1,7,8-TRIFLUORONAPHTHALENE-2-NAPHTHOL, AND METHODS FOR PRODUCING LIQUID CRYSTAL COMPOUNDS USING SAME | DAINIPPON INK & CHEMICALS (JP) | 2011-02-16 | — | — | EP | disclosed |
| US-7214835-B2 | 1,7,8-Trifluoronaphthalene-2-naphthol, and method for producing liquid crystal compound using same | DAINIPPON INK & CHEMICALS, INC. (JP) | 2007-05-08 | — | — | US | disclosed |
| US-20060163537-A1 | 1,7,8-Trifluoronaphthalene-2-naphthol, and method for producing liquid crystal compound using same | DAINIPPON INK AND CHEMICALS, INC. (JP) | 2006-07-27 | — | — | US | disclosed |
| EP-1544187-A1 | 1,7,8-TRIFLUORONAPHTHALENE-2-NAPHTHOL, AND METHOD FOR PRODUCING LIQUID CRYSTAL COMPOUND USING SAME | DAINIPPON INK AND CHEMICALS, INC. (JP) | 2005-06-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060163537-A1 | 1,7,8-Trifluoronaphthalene-2-naphthol, and method for producing liquid crystal compound using same | NOC2L, SNX2, NEFM | TDP1 1093/4885TSHR 3402/4885LTA4H 1821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.